Japan approved its 39-trillion-yen economic stimulus package on November 22. It does not explicitly state that the drug price revision…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS UK AstraZeneca CEO Brennan Says Investment in Japan, a “Very Important Market,” Will Continue
December 1, 2011
-
REGULATORY CSIMC Approves Outline of Plan to Promote Generic Drug Use
December 1, 2011
-
REGULATORY CSIMC Expert Member Yoshimura Says Conditions Must Improve to Promote Generics
November 30, 2011
-
BUSINESS AZ to Bolster Its Top Position in Breast Cancer Area
November 29, 2011
-
REGULATORY Record 101 Generics from 30 Companies Listed for Aricept
November 29, 2011
-
REGULATORY MHLW Says Sept Drug Price Settlement Rate Dips to 78.1%, Falling Below 2009 Level
November 28, 2011
-
REGULATORY CSIMC to Discuss Additional Price Cuts for Long-Listed Drugs
November 28, 2011
-
ORGANIZATION Economic Losses Due to Illness, Injury Total ¥3.3 Tril. Annually in Japan: ACCJ
November 28, 2011
-
REGULATORY DPJ's Subcommittee for PAL Amendment Begins Deliberations Nov. 28, to Compile Opinion by End-Jan
November 25, 2011
-
ORGANIZATION MSF Japan General Director Expresses Concern Over TPP Negotiations, Possible Generics Price Rise
November 25, 2011
-
REGULATORY Policy Screening Committee Proposes Major Cutbacks in Long-Listed Drug Prices, Additional Decreases Possible
November 24, 2011
-
BUSINESS 25 Leading Drug Makers Report Overall Decline in Sales, Profits in 1st Half
November 24, 2011
-
ACADEMIA JSMO Issues 33 Development Requests for Unapproved Drugs, Indications
November 22, 2011
-
BUSINESS Sanofi, Nichi-Iko to Copromote Latter's Generic Drugs
November 22, 2011
-
BUSINESS Sawai, Nichi-Iko Boost Inventory Ahead of Expected PAL Amendment
November 21, 2011
-
REGULATORY MHLW Study Group Postpones Decision on Relief System for Victims of Health Damages Due to Anticancer Drugs
November 21, 2011
-
REGULATORY After Delay, CSIMC Recommends Listing of Ilaris for Treatment of CAPS
November 21, 2011
-
ORGANIZATION 6 Indian Generics Companies Including Zydus Form Association, to Start Operations This Month
November 18, 2011
-
BUSINESS Teva to Merge Taiyo, Kowa-Teva, Establish “Teva Pharma Japan” in Mid-2012
November 18, 2011
-
BUSINESS Fujifilm, Kyowa Kirin to Set Up Joint Venture for Biosimilars in 2012
November 17, 2011
ページ
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…